By CERBIOS-PHARMA SA
To get in touch with Cerbios-Pharma brings innovative Topical Delivery system and advanced ADC services offers to BIO-Europe, simply fill out the form below.
Subscribe to Supplier
Cerbios-Pharma brings innovative Topical Delivery system and advanced ADC services offers to BIO-Europe
Lugano, Switzerland: – Swiss-based high-potency API specialist Cerbios-Pharma SA (Cerbios) will introduce its contract manufacturing (CMO) services at the upcoming BIO-Europe networking event in Cologne.
This is a repeat appearance at BIO-Europe for Cerbios, which sent a team from its Biological Division to last year’s event in Munich. Once again, Chief Commercial Officer Andrea Tam will lead its presence at BIO-Europe.
AKANO topical delivery
At BIO-Europe 2016, Cerbios will also present products and services from its Chemical Division, particularly its innovative AKVANO® technology, based on lipids dissolved in water-free solvents that open up new possibilities for topically administered dermatological drug delivery.
Cerbios will also be showcasing its outsourcing and licensing opportunities that include oncology, respiratory and dermatology therapies.
“We have a very broad range of interesting offers to discuss with pharma companies, generics developers and bio-ventures at BIO-Europe,” said Mr. Tam.
“These revolve around our advanced expertise in HPAI high potency active ingredients, ADC manufacturing capabilities and the broad range of our CMO services,” he said.
“Since we were last at BIO-Europe we have celebrated our 40th anniversary, while continuing to evolve our original Bioferment activities,” said Mr Tam.
“Most recently, the synergies between our Chemical and Biological divisions is driving the development and manufacturing of exclusive Antibody-Drug-Conjugates (ADCs) in addition to our Probiotics and Recombinants products and services,” Mr. Tam noted.
“In ADC manufacture, we have now formed the PROVEO™ consortium with CMC Biologics of Denmark, together with Germany’s Oncotec and IDT Biologika that can offer a one stop shop service from substance development all the way through to full finish,” he added.
Cerbios-Pharma SA is a privately held company located in Lugano, Switzerland, that specializes in the development and manufacture of both chemical and biological APIs for its partners world-wide. Cerbios specializes in the development and production of high potency active pharmaceutical ingredients (HPAPIs) in the area of fine chemicals and biologicals.
Cerbios Chemical Division offers exclusive, third-party manufacturing services for HPAIs while Biological Division produces monoclonal antibodies, recombinant proteins and pharma probiotics.
Cerbios provides full CMC support to its worldwide partners, including the supply of cGMP clinical batches, registration/validation material and commercially manufactured APIs. Paramount to this is the ability to supply all of the technical documentation and support necessary for a successful registration. Cerbios’ commercial products are marketed worldwide but primarily in Europe, USA, Japan and India.
About BIO-Europe 2016
The BIO-Europe® Conference is the flagship conference for EBD Group, providing life science companies with high caliber knowledge sharing and partnering opportunities.
BIO-Europe has formed the launchpad for many highly successful business partnerships, drawing delegates from all parts of the biotechnology value chain to identify, engage and enter into strategic relationships.
BIO-Europe 2016 is a three-day event opening November 7 at Cologne’s Koeln Messe – Congress Center North, again drawing more than 3,000 industry attendees from some 60 countries, representing more than 1,800 companies.
Partnering at BIO-Europe 2016 is powered by EBD Group’s partneringONE®, the industry’s most advanced networking system, which enables participants to efficiently mine a large pool of potential partners, and identify and pre-arrange private one-to-one meetings with multiple company targets.
More information at: https://ebdgroup.knect365.com/bioeurope/